Member Info for Titania

Sorry 12 people mentioned not 8!

Looks like P Monk presenting this. Either him or 8 people but no mention of Richard Marsden.

https://www.abstractsonline.com/pp8/#!/10476/presentation/10405

I haven't managed to find the Thematic poster session on the 17th at ATS.

I was expecting Richard Marsden not Tom Wilkinson.

Introduction before and questions afterwards not included in the 13 mins.

https://www.abstractsonline.com/pp8/#!/10476/session/432

9:33 AM - 9:46 AM SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalized Due to COVID-19
Tom Wilkinson, Cantab, MBBS, PhD, FRCP. University Hospital Southampton, Southampton, United Kingdom

"Our findings are well aligned with other systematic reviews and meta-analysis results which suggest Type 1 interferons reduce mortality and increase faster hospital discharge among patients with COVID-19 [23], IFN-ß reduces hospitalization length and respiratory symptoms of COVID-19 [21], and IFN-based agents lead to improvements in chest X-rays findings and lower levels of inflammatory cytokines when used in combination with antivirals, corticosteroids, and traditional medicine for SARS, MERS, and COVID-19 [25]."

https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000231

Funding: This work was funded by the Bill & Melinda Gates Foundation (grant number OPP1155935). This provided funding for four of the authors (Aldina Mesic, Emahlea Jackson, Mathias Lalika, and Rena Patel). David Koelle did not receive any funding for this work. The U.S. National Institutes of Health supported Ms. Aldina Mesic’s and Dr. Rena C. Patel’s efforts (D43-TW007267 and R25-TW009345 from the Fogarty International Center and K23AI120855, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. https://www.gatesfoundation.org/ https://www.nih.gov/

Apologies if already posted

https://www.longdom.org/proceedings/inhaled-ifn1b-for-rsv-bronchiolitis-6061.html

The world has gone mad!

Elon Musk buying Twitter for 44 billion dollars and Synairgen only worth 47 million!

"Some experts prefer not to use dexamethasone monotherapy in patients who require supplemental oxygen because of the theoretical concern that corticosteroids might slow viral clearance when administered without an antiviral drug. Corticosteroids have been associated with delayed viral clearance and/or worse clinical outcomes in patients with other viral respiratory infections.11-13 Some studies have suggested that corticosteroids slow SARS-CoV-2 clearance, but the results to date are inconclusive.14-18"

https://www.youtube.com/watch?v=x8rq247E80I

Something to watch over the weekend for those interested. Acceptance that antivirals are required as part of the vaccine strategy in case variants shift too much.

"Ideal COVID-19 treatments are inexpensive, with a good safety profile, and prevent clinical deterioration and hospitalization. Currently, the only therapies with published evidence of benefits early in the course of infection are inhaled interferon (IFN), small molecules, and monoclonal antibodies (mAbs)."

https://www.pnas.org/doi/10.1073/pnas.2119893119

Hope there is no delay to the deep dive data if SNG could be helping these people!

"Model Medicines recently said that strong preclinical data landed MDL-001 an evaluation agreement with the US National Institutes of Health’s Antiviral Program for Pandemics, accelerating the company’s push toward the clinic. The NIH program launched with more than $3 billion to develop next-generation treatments, including those for future viral threats."

https://cen.acs.org/business/next-generation-COVID-19-antivirals/100/i11

https://www.whitehouse.gov/briefing-room/statements-releases/2022/04/05/fact-sheet-the-biden-administration-accelerates-whole-of-government-effort-to-prevent-detect-and-treat-long-covid/

"Synairgen’s Covid treatment can still have a role in severe cases explains CEO Marsden"

https://www.bloomberg.com/quote/SYGGF:US

Further SPRINTER Phase 3 analysis

"As announced on 21 February 2022, Synairgen is in the process of analysing the topline and full dataset from the SPRINTER Phase 3 study in order to better understand all of the findings. The findings of this analysis will be announced without delay once complete in accordance with regulatory obligations and presented and/or published in a peer-review journal."